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Summary
In this work, we combined computational protein-
protein docking with computational and experimental
mutagenesis to predict the structure of the complex
formed by monoclonal antibody 806 (mAb 806) and
the epidermal growth factor receptor (EGFR). We
docked mAb 806, an antitumor antibody, to its epitope
of EGFR residues 287–302. Potential mAb 806-EGFR
orientations were generated, and computational muta-
genesis was used to filter them according to their
agreement with experimental mutagenesis data. Fur-
ther computational mutagenesis suggested additional
mutations, which were tested to arrive at a final struc-
ture that was most consistent with experimental muta-
genesis data. We propose that this is the EGFR-mAb
806 structure, in which mAb 806 binds to an unteth-
ered form of the receptor, consistent with published
experimental results. The steric hindrance created by
the antibody near the EGFR dimer interface interferes
with receptor dimerization, and we postulate this as
the structural origin for the antitumor effect of mAb
806.
Introduction
Excessive signaling from epidermal growth factor re-
ceptor (EGFR) and homolog ErbB2 has been implicated
(Yarden and Sliwkowski, 2001) in a broad spectrum of
epithelial carcinomas, including breast, ovarian, head
and neck, lung, pancreatic, and colorectal cancer. Anti-
body targeting of the extracellular region of these recep-
tors is known to mitigate the effect of aberrant signaling
and to induce an antitumor effect (Harari, 2004; Sridhar
et al., 2003). The crystal structures of the antitumor anti-
bodies Trastuzumab (Cho et al., 2003), Cetuximab (Li
et al., 2005), and Pertuzumab (Franklin et al., 2004)
bound to their respective receptor antigens (ErbB2,
*Correspondence: jgray@jhu.eduEGFR, and ErbB2) have been solved. These structures
have aided in the elucidation of the mechanisms of ac-
tion of these antibodies.
Crystal structures of the EGFR extracellular domain in
the monomeric (Protein Data Bank [PDB] identifiers
1NQL, 1YY9) and dimeric states complexed with ligands
such as TGF-a (1MOX) (Garrett et al., 2002) and EGF
(1IVO) (Ogiso et al., 2002) have been reported. The mo-
nomeric EGFR is autoinhibited due to intramolecular
tethering interactions between the domain II dimeriza-
tion arm and a domain IV b loop (Ferguson et al., 2003).
Figure 1 depicts the EGFR conformation change from
the tethered monomer to a hypothetical untethered state
seen in the dimer, which leads to the formation of the
dimer. The hypothetical extended monomer state is
reached via a 130º counterclockwise rotation of the rigid
body comprised by domains I and II that releases the in-
tramolecular tether in the tethered conformation (1NQL)
and brings domains I and III closer to each other. This
motion frees the dimerization arm to interact with its
counterpart on a second EGFR to form the active EGFR
dimer. While it is possible that ligand binding induces
the EGFR conformational change, the current view is that
the ligand stabilizes the extended conformation from an
ensemble of states sampled by the flexible and dynamic
EGF receptor (Walker et al., 2004).
The antitumor antibody mAb 806 was first described
by Mishima and coworkers (Mishima et al., 2001). mAb
806 binds to the extracellular region of the EGFR when
it is either truncated in EGFRvIII or overexpressed, indi-
cations prevalent in several types of cancers; however,
mAb 806 does not bind the endogenous EGFR in tissues
such as liver and skin (Johns et al., 2002; Luwor et al.,
2001; Mishima et al., 2001). Previous experimental work
with immunoblotting and yeast surface display of EGFR
fragments identified a disulfide bonded loop (amino
acids 287–302) in EGFR domain II that contains the com-
plete mAb 806 epitope (Johns et al., 2004). Subse-
quently, individual residues in the peptide that are ener-
getically important in mAb 806 binding were identified
by using random mutagenesis and yeast surface display
(Chao et al., 2004). These residues appear to be ac-
cessible if residues 6–273 are removed, as they are in
EGFRvIII, but inaccessible in the wild-type tethered
monomer conformation. This is consistent with experi-
mental data that mAb 806 does not bind the receptor
in solution, but binds when the receptor is either immo-
bilized on ELISA plates or denatured by heat (Johns
et al., 2002). To explain these observations, it has been
suggested that a putative intermediate state along the
EGFR conformational transition pathway exists that ex-
poses the mAb 806 epitope residues, thus leading to
stronger antibody binding (Johns et al., 2004). However,
it is not clear if the intermediate state is closer to the
tethered or extended receptor monomer conformation.
Experiments on mAb 806 binding to various mamma-
lian cell lines tend to confirm the notion of an ‘‘interme-
diate’’ state. mAb 806 binds robustly to EGFR mutants
with a reduced tethering capacity through either dele-
tion of the dimerization arm or point mutation (Walker
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402Figure 1. EGFR Conformational Change
(A–C) The dimerization arm, the mAb 806-peptide epitope, and the EGF ligand are colored magenta, red, and cyan, respectively. EGFR domains
are labeled. The intramolecular tether in (A) is highlighted by the box. Upon release of the tether, EGFR in the tethered state ([A], 1NQL) undergoes
a conformational change to a hypothetical untethered, extended monomer whose coordinates are taken from chain A in the dimer (1IVO) for do-
mains I–III and from the tethered monomer (1NQL) for domain IV since this domain is disordered in the dimer. The arrow shows the direction in
which EGFR domains I and II move to reach (B) from (A). The dimer ([C], 1IVO) is formed by interaction of two receptors in the extended state.
EGFR domain IV is not shown in (C). The dimerization arm is proximal to the peptide epitope recognized by mAb 806.et al., 2004). mAb 806 binds poorly to the parental
U87MG cell line that endogenously expresses the wild-
type EGFR (w105 receptors per cell) in the absence of
EGFR gene amplification (Johns et al., 2002). However,
in the A431 cell line where the EGFR is overexpressed
(2 3 106 receptors per cell) due to gene amplification,
mAb 806 recognizes about 10% of the total EGFR mole-
cules (Johns et al., 2002). Recent experiments (Johns
et al., 2005) show that mAb 806 preferentially binds to
immature high-mannose forms of the wild-type EGFR.
When the EGFR is overexpressed, such immature
EGFR forms appear on the cell surface, possibly due
to saturation of specific glycosylation pathways. The al-
tered glycosylation state in this immature receptor may
promote receptor untethering, thus leading to increased
mAb 806 binding. This appears to explain why mAb 806
does not bind wild-type EGFR, but binds a fraction of the
cell-surface EGFR when it is overexpressed.
While there is significant biochemical and cellular in-
formation on mAb 806 binding to EGFR, no molecular
structure has been determined for the mAb 806-EGFR
complex. X-ray crystallization, while providing complete
and high-resolution information, is time consuming and
can be limited by the ability of the complex to form
a crystal. This particular complex is also too large for ac-
curate determination by standard NMR techniques. An
inexpensive and rapid alternative is to use protein struc-
ture prediction tools to create the antibody structure
and computational docking to predict the complex
model. While these tools involve considerable uncer-
tainty, in the recent international blind prediction chal-
lenge, the Critical Assessment of Predicted Interactions
or CAPRI, several docking algorithms (Aloy et al., 2001;
Berchanski et al., 2004; Camacho and Gatchell, 2003;
Comeau et al., 2004; Dominguez et al., 2003; Fernan-
dez-Recio et al., 2003; Gray et al., 2003b; Li et al.,
2003; Mandell et al., 2001; Ritchie and Kemp, 2000;
Schneidman-Duhovny et al., 2003; Smith et al., 2005;
Wang et al., 2005; Zacharias, 2003) have been tested,and many (Berchanski et al., 2004; Camacho and Gatch-
ell, 2003; Dominguez et al., 2003; Fernandez-Recio et al.,
2003; Gray et al., 2003b; Li et al., 2003; Mandell et al.,
2001; Wang et al., 2005) have produced high-quality pre-
dictions for multiple protein-protein targets in CAPRI
rounds 3–5.
Our current target involves two significant modeling
challenges that have not been previously explored or
have been found to be difficult. First, the structure of
one of the components, mAb 806, is not itself known
and must be predicted with homology modeling. Sec-
ond, the EGFR is quite large and exhibits significant do-
main flexibility. However, by incorporating biochemical
information available on mAb 806 and EGFR, and by it-
eratively testing docking predictions by experimental
mutagenesis, the accuracy of docking predictions can
be improved to the point of reasonable confidence in
the final result. Experimental data about the binding in-
terface are commonly employed in docking studies
(for a recent review, see van Dijk et al. [2005]), and
here we highlight only a few representative examples.
In single-mutagenesis studies, the change in binding af-
finity is measured after mutation of a particular residue.
Loss of binding after mutation at a particular position
suggests, but does not guarantee, that the mutated res-
idue is located at the binding interface. Neutral binding
affinity change at a position does not necessarily sug-
gest that a residue is not located at the interface, as it
may be possible that it simply does not contribute
much to the binding energy. These cases are observed
in the interaction of a heterotrimeric G protein subunit
with other subunits and a transmembrane receptor
studied with affinity tests of 100 mutants of the central
subunit (Onrust et al., 1997). When a method assumes
that nondisruptive mutation positions are explicitly not
at the protein-protein interface and disruptive or par-
tially disruptive positions are, the models can be very
sensitive to the experimental information (Herzyk and
Hubbard, 1998). Appropriately, HADDOCK is one
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tal information in an ambiguous fashion, allowing for
the use of NMR chemical shift perturbations and resid-
ual dipolar couplings in addition to mutagenesis data
(Dominguez et al., 2003). Mutagenesis can also be
used subsequent to docking for validation. A complex
of tissue factor, factor VIIa, and factor Xa constructed
by docking allowed for rational selection of target resi-
dues for site-directed mutagenesis that were in agree-
ment with the model (Norledge et al., 2003). In a study
with a target similar to the current work, a homology
model of a recombinant antibody was docked to the a-
bungarotoxin and subsequently validated by mutations
suggested by human inspection of the two putative
binding models (Bracci et al., 2003). Massova and Koll-
man (1999) developed a model for ‘‘computational ala-
nine scanning’’ by using a molecular mechanics-Pois-
son-Boltzmann surface area (MM-PBSA)-based energy
function and applied it to study the interactions of the
oncoprotein Mdm2 to the N-terminal stretch of tumor
suppressor protein p53. Recently, explicit energy calcu-
lations on an ensemble of mutated sequences were
exploited to improve predictions of the folding of lat-
tice proteins (Nanda and DeGrado, 2005). Similarly for
protein-protein docking model structures, more infor-
mation might be gleaned from mutagenesis experi-
ments by exploiting energy calculations for the specific
mutations.
Our objective is to predict the mAb 806-EGFR com-
plex structure by using a protocol that combines the
protein docking program RosettaDock (Gray et al.,
2003b) with computational (Kortemme and Baker,
2002) and experimental mutagenesis. The RosettaDock
method employs a low-resolution rigid-body Monte-
Carlo search followed by an all-atom, simultaneous op-
timization of backbone displacement and backbone-de-
pendent side chain rotamer conformations by using
Monte-Carlo minimization. RosettaDock and the Roset-
taInterface mutagenesis program (Kortemme and
Baker, 2002) both capture side chain flexibility and em-
ploy a comprehensive energy function dominated by
van der Waals interactions, solvation, and hydrogen
bonding. The performance of the RosettaDock algo-
rithm has been successfully tested (Daily et al., 2005;
Gray et al., 2003a) in several rounds of CAPRI, and Ro-
settaDock correctly predicted the complex structure of
dockerin and cohesin in CAPRI round 4 by using a ho-
mology model with considerable structural errors (Daily
et al., 2005). Here, we propose to use the available mu-
tagenesis data on mAb 806 binding to EGFR (Chao
et al., 2004) to not only identify interface residues, but
to verify via computational mutagenesis (Kortemme
and Baker, 2002) if a mutation produces similar out-
comes in a docking decoy and in experiments. To the
best of our knowledge, this is the first instance in which
computational and experimental mutagenesis are itera-
tively combined with docking to isolate native-like de-
coys from other incorrect docking solutions.
Results
Figure 2 outlines our overall protocol for the determina-
tion of the mAb 806-EGFR complex structure. Experi-
mental results support the hypothesis that mAb 806binds a transitional form of the EGFR, but the exact loca-
tion of this conformation along the path from tethered
monomer to hypothetical extended monomer is un-
known and its structure has not been determined. There-
fore, we use the experimentally determined peptide epi-
tope, instead of the full EGFR protein, as the docking
partner for mAb 806. We independently docked mAb
806 to five crystal structure conformations of the EGFR
peptide (residues 287–302), which contains the mAb
806 epitope as demonstrated by previous experiments.
Since a crystal structure is also not available for mAb
806, we built a homology model by using the Web Anti-
body Modeling (WAM) tool (Whitelegg and Rees, 2000).
We use the RosettaDock algorithm to generate decoys,
or potential mAb 806-EGFR structures, and rank them by
using an all-atom energy function. Next, we perform
computational mutagenesis on low-energy decoys to
identify mAb 806-peptide orientations in conformity
with published experimental mutagenesis data (Chao
et al., 2004). We structurally superpose the models
with the EGFR ectodomain crystal structure to eliminate
unphysical orientations of the antibody that arise from
docking mAb 806 to the peptide epitope without consid-
ering the steric hindrance due to the nonpeptide EGFR
residues. In this manner, we identify three potential
models, and additional computational mutagenesis re-
sults suggest new aromatic residue substitutions to dis-
tinguish between these models. We select the final mAb
806-EGFR complex model as the one most consistent
with these new experimental results.
Figure 2. Protocol for the Prediction of the mAb 806-EGFR Complex
Structure
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Conformation between the Tethered and the
Untethered EGFR Crystal Structures
Figure 3 shows the mAb 806-peptide epitope (amino
acid sequence CADSYEMEEDGVRKC) backbone con-
formations from the dimer crystal structures (1IVO,
1MOX) superposed onto that of the tethered monomer
(1NQL). The pairwise Ca rmsd between the different con-
formations is within 2 A˚ (Table 1) for the epitope residues
and 1–1.5 A˚ for the larger EGFR segment 275–305 (data
not shown). There is a tight consensus between the
independently determined peptide backbones in the
N- and C-terminal regions (287–291 and 299–302); varia-
tion in the backbone occurs between residues 292 and
298. The consensus between these conformations sug-
gests an overall stability of the peptide due to the disul-
fide bond between the N- and the C-terminal cysteines.
On the other hand, the availability of different backbone
conformations is fortunate because it allows for the use
of different starting structures in the docking simula-
tions to capture the variability inherent in the exposed
peptide epitope.
A closer look at the peptide conformation from the
tethered monomer reveals that the Cb of residue E293,
a known hotspot for mAb 806 binding, is oriented differ-
ently relative to the dimer crystal structures (Figure 3A).
We term the backbone conformation of the peptide in
1NQL as the ‘‘flipped out’’ conformation, as the side
chain of E293 is exposed at the surface of the tethered
monomer. On the other hand, the peptide conformations
in 1MOX and 1IVO are ‘‘flipped in,’’ as the E293 side chain
points toward the protein interior and is inaccessible
to antibody. The average pairwise angle between the
Ca-Cb vectors at position 293 from the various dimer
crystal structures is 15.4º, indicating that the side chains
have similar directionality. In contrast, the average pair-
wise angle between the Ca-Cb vector at position 293 from
the 1NQL peptide and those from the dimer peptide con-
formations is 130.5º, signaling a complete reversal of the
Cb directionality. Although only the Cb coordinate for
E293 is resolved in 1NQL, the orientation change is sup-
ported by the corresponding change in the directionality
of the bulky Y292, which is clearly resolved in all of the
structures, and M294, which has only a resolved Cb in
1NQL (Figure 3B). For the dimers alone, the orientation
of the Ca-Cb vectors differ on average by 34.6º and
23.6º for positions 292 and 294, respectively. However,
the Ca-Cb vectors of residues 292 and 294 in the 1NQL
peptide change directions by 84.4º and 91.6º, respec-
tively, on average from the dimer structures. By the
same measure, the remaining epitope side chains are
nominally oriented in the same direction in both the
dimer and the monomer crystal structures. Thus, the
crankshaft-type move involving residues 292–294
essentially reverses the directionality of these side
chains without affecting the remaining peptide residues.
It is unclear if the crankshaft move is due to the dynamics
of the peptide epitope in solution or if it reflects condi-
tions of the crystallization process.
mAb 806 Is Predicted to Adopt a Predominantly
Canonical Structure
Potential uncertainties in the WAM homology model are
restricted to the antigen binding CDR (complementarity-determining region) loops, as the antibody framework is
highly conserved (Chothia and Lesk, 1987). In general, all
CDR loops except H3 can be assigned to canonical clas-
ses that depend on the identity of key residues in the an-
tibody sequence (Al-Lazikani et al., 1997; Chothia and
Lesk, 1987). A comparative analysis of the main chain
CDR conformations (excluding CDR H3) in high-resolu-
tion antibody structures revealed that 71 out of 79 CDR
loops had a crystal structure conformation very close
to the standard conformation of the respective canonical
classes (Al-Lazikani et al., 1997). Of the remaining eight,
six differ in the orientations of a single peptide group,
and two in CDR H2 involve nonstandard conformations
that are allowed by the presence of three glycine resi-
dues in a surface loop.
With the exception of a few residues, the amino acid
sequences for mAb 806 CDRs L1–L3, H1, and H2 are
nearly identical to the corresponding sequences in
antibody M02/05/01 (PDB 1C12, resolution 2.6 A˚). These
five CDRs are assigned (http://antibody.bath.ac.uk/
autoalign.html) identical canonical conformations (2, 1,
1, 5, and 1) in both antibodies. These CDR backbone
conformations in the homology model are essentially
identical to the respective conformations in PDB 1C12.
MAb 806 has a 7 residue CDR H3 (AGRGFPY). This is
a short loop with a small conformational space and few
reasonable possibilities for placement. The closest ho-
molog (GGTGFPY) is found in CDR H3 of antibody
PC282 (PDB 1KCV, resolution 1.8 A˚), which also has
CDRs H1 and H2 that are homologous with mAb 806.
The CDR H3 regions in the homology model and PDB
1KCV align with a Ca rmsd of 1.2 A˚, suggesting that
WAM accurately models the local conformation of CDR
H3. However, with a global alignment of both the light
and heavy chains, the Ca rmsd for the CDR H3 residues
increases to 5.3 A˚, even though the rmsd for the antibody
as a whole isw1 A˚. This indicates that the positioning of
the H3 loop relative to the framework is altered between
mAb 806 and 1C12. This alteration might originate from
the differences in the sequence of the H3 itself or the
N-terminal stem region (CVT versus CAR for PDB
1KCV) or from variations in the packing at the light-heavy
chain interface.
mAb 806-Peptide Docking, Mutagenesis,
and Structural Superposition
The RosettaDock docking algorithm captures side chain
flexibility by using a backbone-dependent rotamer li-
brary, but it does not model protein backbone flexibility.
To allow for variability in the peptide backbone confor-
mation, we used RosettaDock to independently dock
mAb 806 to each of the five peptide backbone conforma-
tions from the EGFR crystal structures, generating 105
decoys in each simulation. We isolated the top 2000
decoys by energy from each run and clustered these
by using a hierarchical clustering algorithm with a tight
clustering radius of 0.5 A˚. This resulted inO(100) clusters
from each run. Each cluster is represented by the decoy
with the lowest energy in the cluster, and the cluster size
is the number of decoys in the given cluster. Clusters are
numbered in order of decreasing cluster size.
In the next stage of our protocol, we used the Roset-
taInterface computational mutagenesis approach (Kor-
temme and Baker, 2002) to identify docking clusters
Structural Model of the mAb 806-EGFR Complex
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EGFR Crystal Structures
(A and B) Superposition of the mAb 806-pep-
tide epitope backbone from different EGFR
crystal structures. (A) Change in E293 side
chain directionality; (B) alternate view addi-
tionally showing side chains Y292, M294,
and R300. The ‘‘flipped out’’ backbone and
side chains from the tethered monomer
(1NQL) are shown in red; the ‘‘flipped in’’
backbone and side chains from the dimers
are shown in green and CPK colors, respec-
tively; and the disulfide bond is shown in or-
ange. Side chains or b carbons, as available
in the crystal structure, are shown for labeled
residues.that were consistent with experimental data for the mAb
806-EGFR system. The RosettaInterface algorithm em-
ploys the Rosetta energy function to estimate the change
in the binding free energy (DDG) of a protein-protein
complex due to residue mutations. We retained the
hard cutoff ofDDGcalc > 1.0 kcal/mol to qualitatively iden-
tify hotspot residue mutations, since Kortemme and
Baker (2002) found that this criterion was sufficient to
correctly identify 80% of hotspot residue mutations in
a set of 19 high-resolution protein-protein complex crys-
tal structures. 21.0 < DDGcalc < 1.0 indicates a neutral
mutation, while DDGcalc < 21.0 indicates a mutation
that potentially increases binding affinity. Experimental
data on the mAb 806-EGFR system has been published
by Chao and coworkers, who used random mutagenesis
and yeast surface display to identify individual residues
in the peptide that are energetically important in mAb
806 binding (Chao et al., 2004). It was shown that four
peptide residue mutations (E293K, G298D, G298S,
V299D) result in a large binding loss, with a DDG > 5
kcal/mol. Six mutations (E293A, E293D, E293G, D297Y,
G298A, K301E) result in partial binding loss, with DDG
w2 kcal/mol. Thirteen EGFR mutants (G288A, A289K,
D290A, S291A, Y292A, M294A, E295A, E296A, D297A,
V299K, V299A, R300A, and K301A) retain wild-type bind-
ing. The data suggest that residue E293 is particularly im-
portant for mAb 806 binding, as conservative (E293D),
nonconservative (E293K), and alanine mutations all re-
sult in binding loss. Computational mutagenesis was
used to predict the effect of these 23 residue mutations
in the decoy clusters obtained from docking. The com-
putational results were compared to the experimental
mutagenesis results, and we refer to a match between
the two results as a ‘‘hit.’’ We then filtered the clusters
by stipulating at least 5 hits for the 10 mutations that
are known to produce at least some binding loss exper-imentally, and 10 hits for the 13 mutations that retained
wild-type binding. The accuracy of the computational
mutagenesis technique does not allow us to exactly
match the experimental DDG values or draw distinctions
between experimental mutations that cause partial or
large binding loss. After application of the mutagenesis
filter, 35 clusters remained that were broadly consistent
with the experimental mutagenesis data.
Next, we structurally superimposed docking clusters
that cleared the mutagenesis filter with the tethered
monomer to identify and eliminate clusters with mAb
806-peptide orientations that are unphysical in the con-
text of the full-length EGFR. These unphysical orienta-
tions arose from docking mAb 806 to the peptide epitope
without considering any steric hindrance due to the non-
peptide EGFR residues. Since mAb 806 does not bind the
tethered EGFR in experiments, the superposition could
legitimately result in clashes of mAb 806 residues with
the nonpeptide EGFR residues. Therefore, decoys were
eliminated only if they contained severe clashes of the
antibody with EGFR residues that are not predicted to
move relative to the peptide during the conformational
change from tethered monomer to extended dimer. By
the same token, we retained decoys that had minor
clashes of less than five amino acids with the EGFR ecto-
domain, since antibody binding may relieve such clashes
via an induced fit mechanism. Thus, the superposition
filter eliminates most of the physically unrealistic mAb
806-peptide orientations without being overly restrictive
regarding allowable orientations at this stage.
At the end of this procedure, three clusters of the mAb
806-EGFR peptide complex structure remained and
were labeled as models 1, 2, and 3. Table 2 lists the com-
putationally calculated DDG values for these models for
the EGFR residue mutations that lead to loss of mAb 806
binding. The peptide backbones in these models come
Structure
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and 2 use the ‘‘flipped in’’ peptide conformation from
the dimer (1IVO chain A), while model 3 uses the ‘‘flipped
out’’ backbone from the tethered monomer (1NQL). The
three models have 5, 6, and 6 hits, respectively, suggest-
ing qualitative agreement between computational and
experimental mutagenesis for the binding loss muta-
tions. Model 1 has 11 of 13 hits for the neutral mutations,
while models 2 and 3 produce 13 of 13 hits (data not
shown).
Apart from these three clusters, ten other clusters that
produce at least four of ten binding loss hits also satisfy
the structural superposition criterion. However, we elim-
inated these clusters for either of two reasons: the cluster
either had no binding loss hits for any of the important
E293 mutations, or it produced hits for only the E293
mutations and no hits for any of the other mutations.
Interface Side Chain Interactions
in the Preliminary Models
Figure 4 shows the mAb 806-peptide orientations and
the positions of key side chains in the three models,
and Table 3 shows the residue-level interface contacts
for peptide residues 293–301. In all models, the peptide
residues interact primarily with residues from CDRs L3
and H2. In model 1, all peptide residues except V299,
K301, and C302 contact the mAb 806 CDRs. In model
2, residues 288–291, 297, 299, 301, and 302 do not con-
tact the antibody. Model 3 interactions are different,
with all residues except 2872289 and 300 involved in in-
terface contacts. In model 1, E293 contacts residues in
CDRs L2 and H3. In models 2 and 3, E293 makes similar
contacts with CDR H2 residues. D297 makes one and
zero contacts in models 1 and 2, respectively, while, in
model 3, D297 is buried in a pocket formed by 5 residues
from CDRs L2, L3, and H3. Interestingly, models 1 and 2
are similar in global arrangement, but model 3 differs
Table 1. Peptide Backbone Conformational Differences
1IVO:B 1MOX:A 1MOX:B 1YY9 1NQL
1IVO:A 0.94 1.76 0.84 0.85 1.10
1IVO:B 1.93 1.27 1.13 1.41
1MOX:A 1.49 1.69 1.69
1MOX:B 0.63 1.03
1YY9 0.95
Pairwise Backbone Ca Rmsd Values for Peptide Conformations from
EGFR Crystal Structures, Residues 287–302. Data are also shown
for the peptide from a recently published EGFR crystal structure
(PDB 1YY9), which was not used in the docking simulations.from either of them. Model 2 may be obtained from model
1 by rotating the peptide about the axis shown in Fig-
ure 4A.
Position of mAb 806 with Respect to the Full-Length
EGFR Conformation Obtained via Superposition
The presence of a hypothetical ‘‘intermediate’’ state
formed by receptor untethering has been postulated
(Johns et al., 2004) based on the observation that mAb
806 does not bind the tethered EGFR. Apart from this,
it is not clear if this ‘‘intermediate’’ state is close to the
tethered EGFR, or if it resembles the hypothetical ex-
tended monomer in Figure 1B. In Figure 5, we show
the relative position of mAb 806 and the full-length
EGFR in the three models after structural superposition
with the tethered (Figures 5A–5C) and the hypothetical
extended monomer states (Figures 5D–5F). In the super-
position of model 1 with the tethered EGFR, the antibody
light chain has minor clashes (but not interpenetration)
with residue fragment 261–286 and also parts of domain
III. Superposition of model 2 with the tethered EGFR is
similar to model 1, except that the heavy chain is in-
volved in the clashes. In model 3, the antibody light
chain entirely interpenetrates into the EGFR dimeriza-
tion arm, and clashes (not seen in the figure) of the heavy
chain with parts of EGFR domain IV also occur.
The situation is different for the structural superposi-
tion with the hypothetical extended monomer. For
models 1 and 2, there is complete interpenetration of
the antibody and EGFR domain III. For model 3, the
EGFR transition from the tethered to the untethered
but nondimer state eliminates most of the interpenetra-
tion, and visual inspection confirms that only some mi-
nor clashes remain. However, there are also new minor
clashes between the heavy chain and EGFR residues
that occur distal to the peptide.
These observations indicate that the location of the in-
termediate state is close to the tethered conformation if
model 1 or 2 is correct. The minor clashes of models 1
and 2 with the tethered state can be relieved via local
movement of domains I, II, and III relative to the peptide.
The required movements are within the range of the ob-
served EGFR conformational change between the un-
tethered monomer and extended dimer crystal struc-
tures (Experimental Procedures). However, due to the
severe clashes with domain III in the hypothetical ex-
tended monomer, the mAb 806-peptide orientation in ei-
ther of these models does not support an intermediate
close to this EGFR conformation. If model 3 were the cor-
rect binding mode, the superposition indicates an ‘‘inter-
mediate’’ state close to the hypothetical extendedTable 2. Initial Computational Mutagenesis Filter
Model
Number
Cluster
Number
Crystal
Structure
Cluster
Size
E293D
(+)
E293K
(2)
E293A
(+)
E293G
(+)
D297Y
(+)
G298A
(+)
G298S
(2)
G298D
(2)
V299D
(2)
K301E
(+) Hits
1 10 1IVO:A 12 0.6 1.2 0.7 1.0 0.0 2.5 2.3 3.0 0.0 0.0 5
2 53 1IVO:A 3 1.3 1.8 0.9 1.2 20.1 1.8 2.2 4.9 0.0 0.3 6
3 11 1NQL:A 27 1.3 1.5 1.3 1.4 40.3 0.4 0.2 1.0 0.0 0.4 6
DDG, in kcal/mol, from RosettaInterface Computational Mutagenesis for Clusters that Pass the Mutagenesis Filter and the Structural Superpo-
sition Elimination Procedure. Only EGFR mutations that lead to binding loss experimentally are listed. DDG > 1.0 indicates a hit (bold). The + or2
signs, respectively, signify that the mutation resulted in partial or large binding loss in experiments (Chao et al., 2004).DDG > 10 usually indicates
a severe steric clash between side chains. No distinction is made between + and 2 mutations in the definition of a hit.
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(A–C) The mAb 806-peptide interface in the preliminary models. (A) Model 1; (B) model 2; (C) model 3. The mAb 806 light and heavy chains are
colored yellow and blue, respectively. The disulfide bond between EGFR residues 287 and 302 in the peptide epitope is shown in orange. In all
three models, E293 makes energetically important contacts at the interface with either CDR H3 (model 1) or CDR H2 (models 2 and 3). Model 2
may be obtained from model 1 by rotating the peptide about the axis shown in (A). In models 1 and 2, M294, E295, and R300 point toward the
interface, and D297 points away from the interface. The reverse is true for model 3.monomer. The superposition with the hypothetical ex-
tended monomer has only minor clashes, in contrast
with the interpenetration seen for the tethered monomer.
The minor clashes with the hypothetical extended mono-
mer can be relieved by local motion of the dimerization
arm and residues 303–310 distal to the peptide epitope
while keeping the mAb 806-peptide orientation constant.
Experimental Design to Discriminate between
the Three Models
Given the completely different realizations of the inter-
mediate state from models 1 and 2 and model 3, we per-
formed further computational and experimental muta-
genesis to discriminate between the models. We
computationally mutated each peptide residue in the
three mAb 806-peptide models to each one of the other
17 amino acids (excluding Cys and Pro). For several aro-
matic substitutions, we predicted a loss of binding (large
positive DDG) due to steric clashes of the mutant side
chains with the antibody CDRs. The interesting aspect
of these predictions was the differences in the trends
exhibited by models 1 and 2 compared to model 3 for
aromatic substitutions of residues 293–301 (Table 4). In
general, the majority of the aromatic substitutions were
predicted to diminish binding in models 1 and 2, but
were predicted to be neutral in model 3. We tested the
predictions by performing a new set of site-directed
mutagenesis experiments. We list the results of these
experiments in Table 4, and compare them to the com-
putational predictions for the three models. Aromatic
substitutions of residues E293 and D297 result in bindingloss, while the remaining aromatic mutations are neutral
toward mAb 806 binding. Only the predictions for model
3 are consistent with this trend, while the predictions for
models 1 and 2 are mostly inconsistent. Based on these
observations, we propose that the relative orientation of
mAb 806 and the peptide epitope in the mAb 806-EGFR
complex is well approximated by model 3. This also im-
plies that the intermediate EGFR state recognized by the
antibody is closer to the hypothetical extended mono-
mer than the tethered monomer state. The coordinates
of this model have been deposited in the Protein Data
Bank with code 2EXP.
Characteristics of the Proposed Structure
of the mAb 806-EGFR Complex
The proposed structure (Figure 6A) was created by struc-
turally aligning model 3 and the hypothetical extended
monomer state. These coordinates have been deposited
in the PDB with code 2EXQ. The interface buries 1224 A˚2
of surface area between the peptide and the antibody, in-
cluding 721 A˚2 of buried hydrophobic surface and 503 A˚2
of buried hydrophilic surface (calculated by using Nac-
cess [Hubbard and Thornton, 1993]). The interface incor-
porates 16 antibody CDR residues and all peptide resi-
dues except C287, G288, A289, and R300. The mAb
contacts include 1, 2, and 3 residues on CDRs L1, L2,
and L3, respectively, and 3, 5, and 2 residues on CDRs
H1, H2, and H3, respectively. There are seven hydrogen
bonds across the interface: E293-Y50H, Y292-N56H,
E295-R97H, K301-A92L, Y292-S54H, E296-A33H, and
D297-Y91L (in decreasing order of calculated RosettaTable 3. Antibody Interface Residues
Peptide Side Chain Model 1 Model 2 Model 3
E293 L: H50, Y91, W96; H: A95, F99 H: Y50, S52, S54, N56 H: Y50, S52, Y53, S54, N56
M294 H: D31A, F32 L: Y91, A92, F94 H: D31A, Y53
E295 L: W96; H: A33, N35, Y50, S52 L: Y91; H: A95 H: R97
E296 H: Y50, S52, Y53 L: N32, H50, Y91 L: Y91, W96; H: F32, A33
D297 H: N56, R58 — L: Y49, H50, Y91; H: R97, F99
G298 L: F94; H: Y50, R58 H: G96, R97 H: R97
V299 — — L: N32, H50, Y91
R300 L: N32, Y91, A92, Q93 H: D31A, F32 —
K301 — — L: N32, Y91, A92
Antibody CDR Residues that Contact Peptide Residues in the Three Models. A contact is made when two side chains have at least one nonhy-
drogen atom pair within 4 A˚ of each other. Antibody residues follow Chothia numbering. The light (L) and heavy (H) chain CDR regions are res-
idues 24–34, 50–56, 89–97 and 26235, and 50265 and 95–102.
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liminary Models with EGFR Crystal Structures
(A–F) Structural superposition of models 1, 2,
and 3 with the (A–C) tethered and the (D–F)
hypothetical extended monomer conforma-
tion lacking domain IV. The EGFR dimeriza-
tion arm is colored magenta, EGFR residues
261–286 (postdimerization arm segment) are
brown, the mAb 806-peptide epitope is red,
and all other EGFR residues are green. The
EGF ligand (not shown in the tethered
EGFR) is colored cyan. mAb 806 light and
heavy chains are shown in yellow and blue,
respectively. The final proposed model is
(F). In the model, mAb 806 binds the hypo-
thetical extended monomer with minor
clashes of the antibody with the dimerization
arm (magenta) and EGFR residues 303–310.hydrogen bonding energy, where Y50H refers to the Tyr
at residue position 50 of the heavy chain, etc.). Several
residue pairs also make extensive hydrophobic con-
tacts: D297-Y91L, D297-R97H, Y292-Y53H, E296-A33H,
M294-Y53H, K301-A92L, D297-Y49L, and E293-N56H
(in decreasing order of Rosetta van der Waals attractive
energies). The intermolecular contacts that contribute
the most to the total binding energy in the Rosetta calcu-
lations are E293-Y50H and D297-Y91L. The residue-level
interactions as elucidated by the model suggest expla-
nations for the energetics seen in the experimental muta-
genesis. E293 mutations (to D, G, or K) cause binding loss
due to the loss of a hydrogen bond to Y50H and the loss
of hydrophobic contacts with CDR H2 residues (Fig-
ure 6B). The binding loss due to the D297Y mutation
can be attributed to the steric repulsion between the mu-
tant side chain and the aromatic side chains forming the
antibody pocket (Figure 6C).
Discussion
The prediction of antibody-antigen complex structures
is critical to rational biopharmaceutical design, as the lo-
cation of neutralizing epitopes on cell surface receptorscarries significant information regarding the receptor’s
structure/function relationships in normal and diseased
physiology. A particular challenge in the prediction of
antibody-antigen docking is the hypervariability of the
energetically important antibody CDR loop H3. An ad-
vantage for prediction of antibody-antigen-docked
structures over other complexes is the knowledge that
CDR loops generally dominate antigen contacts; how-
ever, even so, in the latest CAPRI open challenge to
compare computational docking algorithms, the statis-
tics for successful antibody-antigen complex formation
were no better than for other complex types, and, in
some cases, they were significantly worse than average
(Janin, 2005; Mendez et al., 2003, 2005; Vajda and Ca-
macho, 2004; Wodak and Mendez, 2004). In this work,
we have attempted to combine computational and ex-
perimental mutagenesis to discriminate false positives
among candidate antibody-antigen-docked structures.
Due to the unavailability of the structure of the full-
length intermediate EGFR conformation recognized by
mAb 806, we split the structure prediction problem
into two parts. First, we created an energetically favor-
able docking model of mAb 806 bound to the 16 residue
EGFR epitope (Figure 4). Next, we inferred the global
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409structure of the complex (Figures 5F and 6) by superim-
posing this model with the EGFR ectodomain crystal
structure and using known information regarding
EGFR conformational change to predict the relative ar-
rangement of the antibody and the EGFR. Accordingly,
the proposed structure of the 806-EGFR complex
(Figure 6A) has two important characteristics corre-
sponding to two aspects of the structure prediction
problem.
The first important characteristic is that if the energet-
ically favorable antibody-peptide orientation seen in
model 3 is to be permitted without steric hindrance
from the remaining EGFR residues, the EGFR molecule
has to adopt a conformation that is in the conformational
vicinity of the hypothetical extended state rather than
the tethered monomer. This conclusion arises because
the dimerization arm residues clash with the antibody
residues when model 3 is superimposed with the teth-
ered monomer (Figure 5C). The final structure built by
using the hypothetical extended monomer state of
EGFR retains minor van der Waals bumps between the
antibody and the EGFR that would need to be annealed
by small domain motions of the EGFR. The biological im-
plication of the predicted structure is that the steric hin-
drance created by the mAb 806 in the region of the dimer
interface would prevent receptor dimerization and sub-
sequent tyrosine kinase activation. We postulate this to
be the structural origin of the molecular mechanism by
which mAb 806 induces an antitumor effect. The hypoth-
esis that receptor untethering is a prerequisite for mAb
806-EGFR binding is corroborated by several pieces of
experimental evidence (Johns et al., 2004; Walker
et al., 2004), and our model for the mAb 806-EGFR com-
plex is consistent with these experimental observations.
This mechanism also explains why mAb 806 only binds
cancer cells, as (1) the epitope is always exposed in
the de2-7 cancerous EGFR mutant (residues 6–273
deleted), and (2) improper glycosylation can affect the
Table 4. Mutagenesis Predictions to Discriminate and Validate
Preliminary Models
Mutation Model 1 Model 2 Model 3 Experimental Result
E293Y 0.8 13.7 9.0 —
E293F 22.8 12.0 8.1 —
E293W 3.4 14.0 6.4 —
M294Y 2.2 4.2 20.4 ++
M294F 20.8 1.9 20.2 ++
M294W 15.5 16.8 0.8 ++
E295Y 48.1 0.0 0.4 ++
E295F 36.6 20.7 0.4 ++
E295W 46.7 21.6 0.2 ++
E296W 0.9 2.5 21.3 ++
D297W 20.03 20.1 31.0 +
V299Y 20.3 20.9 20.8 ++
R300Y 17.7 17.9 20.4 ++
R300F 11.1 9.1 20.4 ++
R300W 9.2 8.7 20.4 ++
K301W 0.0 20.1 1.4 ++
Calculated DDG Values for Aromatic Substitutions of Peptide Resi-
dues 293–301 for the Three Preliminary Models. Predictions consis-
tent with experimental results are shown in bold. In the experimental
results column, ++, +, and 2 indicate mutations that lead to zero,
partial, and large binding loss, respectively. DDG > 10 usually indi-
cates a severe steric clash between side chains.relative stability of the tethered state and shift the pop-
ulation toward an extended, untethered state.
The second important characteristic of the model cor-
responding to the antibody-epitope relative orientation
is that it requires the ‘‘flipped out’’ peptide epitope back-
bone observed only in the tethered crystal structure
(1NQL), and not in the dimer (1MOX or 1IVO) or the re-
cently published structure of the tethered EGFR com-
plexed with Cetuximab (1YY9) (Li et al., 2005). However,
only the ‘‘flipped out’’ peptide conformation has the spe-
cific side chain orientations that correctly capture the
differences in the effect of peptide residue mutations
on mAb 806 binding. All EGFR residues essential for
mAb 806 binding are contained in the peptide (Johns
et al., 2004), but experimental alanine mutations at all
positions except E293 and G298 are neutral toward
mAb 806 binding (Chao et al., 2004). Only nonconserva-
tive mutations (D297Y, V299D, and K301E) indicate the
energetic importance of other residues. Each of the pre-
liminary models cleared the mutagenesis filter based on
these data (Table 2). However, our new experimental re-
sults (Table 4) indicate that aromatic substitutions at po-
sitions 294–296 and 299–301 do not decrease binding
affinity. Of the three models, only model 3 correctly pre-
dicts the majority of these neutral mutations. The differ-
ence in the predictions of model 3 compared to models 1
and 2 can be traced to a change in the directionality of
residue E293 between the ‘‘flipped out’’ and ‘‘flipped
in’’ peptide conformations (Figure 3).
In the ‘‘flipped in’’ conformation (models 1 and 2), the
orientations of the Ca-Cb vectors of residues 293 and
297 differ by an average angle of 118º, indicating that
the side chains point in nominally opposite directions.
Thus, D297 has a significantly reduced chance of con-
tacting antibody residues at the interface if E293 is at
the interface and vice versa. However in the ‘‘flipped
out’’ conformation, this angle is 9.5º, indicating that the
side chains of E293 and D297 have a similar directionality
and can occur at the interface simultaneously. Thus,
model 3 captures the binding loss due to substitutions
at both E293 and D297, while models 1 and 2 show agree-
ment only with the E293 binding loss mutations. Simi-
larly, in the ‘‘flipped in’’ conformation, M294 and R300
are oriented such that the side chains are buried at the in-
terface if E293 is an interface residue. Consequently, in
models 1 and 2, E293 binding loss mutations also imply
binding loss due to M294 and R300 aromatic substitu-
tions (Table 4). In the ‘‘flipped out’’ peptide conformation,
the direction of residue E293 results in M294 and R300
pointing opposite of E293. Therefore, the ‘‘flipped out’’
side chain orientations in model 3 are consistent with
both the E293 binding loss mutations and neutral aro-
matic substitutions of M294 and R300.
Since the model is dependent on the computational
mutagenesis results, it is important to analyze the limita-
tions of this technique and the mismatches between the
final model and the experiment. In the original RosettaIn-
terface work, Kortemme and Baker (2002) were able to
successfully identify 79% of hotspots and 68% of neutral
interface residues in a benchmark of 19 protein com-
plexes. This is remarkable given that RosettaInterface
models the residue mutations on a fixed protein back-
bone and does not account for binding loss due to local
unfolding or accommodate mutations that might
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806-EGFR Complex
(A) Proposed structure for the mAb 806-
EGFR complex, created by structurally align-
ing model 3 with the hypothetical extended
monomer conformation. The coloring scheme
is identical to that in Figure 5.
(B) Interface interactions: EGFR residue E293
forms a hydrogen bond with CDR H2 side
chain Y50 and makes several hydrophobic
contacts, mostly with residues in the mAb
806 H2 loop.
(C) EGFR residue D297 is well packed in
a pocket of residues from the mAb 806 L2,
L3, and H3 CDRs.become neutral via local backbone motion in real pro-
teins. Overall, model 3 correctly predicts 33 of 40 (80%)
mutations, including 14 of 16 (87%) new mutations
checked experimentally after the model had been built.
E296W (DDG =21.3) and K301W (DDG = +1.4) are incor-
rectly predicted to be stabilizing and destabilizing, re-
spectively, in model 3, as these mutations are neutral in
experiments. Model 3 incorrectly predicts that mutations
G298A, G298S, V299D, and K301E are neutral when
a binding loss is seen in experiments. The side chains
of V299 and K301 make interface contacts in model 3,
but these interactions are either not accurately modeled
during docking, or the energies of these interactions are
not correctly revealed by computational mutagenesis.
Glycine residues have no side chain and thus tolerate
a relatively wide range of (f,4) values. RosettaInterface
was parameterized by explicitly omitting mutations to
or from glycine residues due to the possibility of back-
bone conformational change. In fact, four of the original
ten binding loss mutations considered involve a change
to or from glycine (E293G, G298A, G298D, G298S). In the
final model, the E293 (f,4) coordinate of the peptide
backbone is located on the Ramachandran map in an
area favored by both glycine and nonglycine residues
(data not shown). Therefore, the E293G mutation might
not change the backbone conformation (the computa-
tional and experimental mutagenesis agree for this posi-
tion). Also, a hit is obtained for the G298D mutation, but
not for the G298A and G298S mutations (Table 2). The
G298 (f,4) coordinate in model 3 is favored for glycine
residues, but it is not permitted for nonglycine residues.The binding loss due to the G298A/S mutations might be
caused by conformational change, explaining why the
effects of these mutations are not captured by our simu-
lations.
There might also be errors in the absolute values of
DDG due to general errors in the energy function. In the
original RosettaInterface work, DDG predictions for mu-
tations involving charged residues were underesti-
mated, even when the residues were qualitatively identi-
fied as hotspots. Likewise, in the present work, the
predicted DDG for the E293K mutation of 1.5 kcal/mol
(Table 2) is less than the experimental result of 5.7 kcal/
mol (Chao et al., 2004), probably due to the simplified
treatment of the electrostatic interactions in the Roset-
taInterface model. Due to the lack of quantitative agree-
ment, as suggested by Kortemme and Baker (2002), we
useDDG greater than or less than 1.0 kcal/mol as the cri-
terion for labeling neutral and binding loss mutations. A
further caveat for these predictions is that we are calcu-
lating DDG values on a model of the docked complex,
rather than a crystal structure. To overcome additional
uncertainties, we oversampled the conformational
space significantly and selected structures with agree-
ment with the experimental mutagenesis data. The qual-
itative agreement of the computational and experimental
mutagenesis on the models to an extent near that of the
agreement of previous calculations on crystal structures
is encouraging.
The docking results are dependent on the accuracy of
the crystal structure conformations of the peptide epi-
tope and the homology model for mAb 806. The disulfide
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411bond between the N- and C-terminal cysteines stabilizes
the peptide backbone conformation and ensures that
a large conformational change (unfolding) is starkly im-
possible. In addition, our use of five peptide conforma-
tions from three independently determined crystal struc-
tures is aimed at capturing the variability in the backbone
conformation seen especially for residues 292–298. For
mAb 806, the backbone conformations of all CDR loops
except H3 are identical to the respective conformations
of antibody M02/05/01, which shares identical CDR
canonical classifications. The backbone conformation
of CDR H3 is similar to the conformation of the homolo-
gous CDR H3 in antibody PC282. Potential errors in the
homology model are restricted to the positioning of
CDR H3 with respect to the antibody framework. While
this is cause for some concern, the short length of H3 is
a mitigating factor. Analysis of the antigen bound confor-
mations of two antibodies with 7 residue CDR H3s
(HYHEL-5 [PDB 1BQL] and D44.1 [PDB 1MLC]) in a pro-
tein-protein docking benchmark (Chen et al., 2003) indi-
cates that the bulk of the interface contacts in these
complexes is contributed by CDRs L3 and H2, and that
CDR H3 plays a diminished role in antigen recognition.
Similarly, in the final model, most of the contacts are
mediated by residues from CDRs L3 and H2, and only
two CDR H3 residues (R97 and F99) contact the antigen.
Any backbone errors in either the peptide or mAb 806
might impact the energetics of binding for individual
peptide residues and result in incorrect predictions for
the mAb 806-peptide orientation. However, the post-
docking mutagenesis results provide strong support
for the model. It is unlikely that the predicted result of
the mutations would be consistent with greater than
80% of experimental results in an incorrect model. Sev-
eral matches with experimental mutagenesis measure-
ments were made after the predictions of the candidate
models, and the new experimental information was not
used in generating the model. Producing robust docking
solutions in spite of errors in the backbone conformation
is not without precedent. In fact, RosettaDock predicted
the cohesin-dockerin CAPRI target (dockerin homology
model with 52% sequence identity) with an 1.17 A˚ inter-
face rmsd and 42% of the native contacts despite signif-
icant deviations in the backbone of the homology-mod-
eled dockerin (Daily et al., 2005).
The mAb 806-EGFR system has served as a test case
for a novel, to our knowledge, approach that combines
protein docking with computational and experimental
mutagenesis to model protein complexes. Computa-
tional mutagenesis is more specific and informative
than using interface contacts to filter docking solutions.
For instance, the fact that M294 is an interface residue in
all of the models (Table 3) does not shed light on the
effect of aromatic substitutions at this position and
therefore has no value in discriminating between the
three models. However, with the computational muta-
genesis calculation, this residue’s experimental results
clearly support only one model (Table 4). As further evi-
dence of the predictive power added by computational
mutagenesis, we have used the protocol developed in
this mAb 806-EGFR study to predict the structure for
CAPRI target 21 (Sir1-Orc1 complex [Hou et al., 2005])
for which 7 neutral mutations and 7 binding loss muta-
tions had been experimentally characterized (Boseet al., 2004; Gardner et al., 1999). The best predictions
by any of the CAPRI participants were of ‘‘medium’’
accuracy (‘‘two-star,’’ i.e., [a] 30%–50% native residue-
residue contacts and ligand or interface rmsd < 5 A˚, or
[b] greater than 50% native residue-residue contacts
and ligand or interface rmsd > 1 A˚ [Mendez et al.,
2005]). We were one of only three groups to produce
such a model out of 37 CAPRI participants. HADDOCK
(Dominguez et al., 2003), which also incorporates bio-
chemical information, achieved a medium-accuracy
prediction as well. In our prediction of this complex,
computational mutagenesis correctly identified three
of the seven binding loss mutations (Y489S, R493G,
A505D) in our best model and in the subsequently re-
leased crystal structure (Hou et al., 2005). These results
are a testament to the quality of RosettaDock’s side
chain refinement protocol and the utility of combining
docking with computational mutagenesis for blind
docking predictions.
In summary, we have proposed a model of the struc-
ture of the mAb 806-EGFR complex by combining a di-
verse set of computational tools to overcome several
modeling challenges. These challenges include antibody
homology modeling, CDR loop uncertainty, a large and
flexible antigen, and subsequent verification of the pre-
dicted model. The model will provide a working hypoth-
esis for further analysis and engineering of mAb 806 for
use in cancer therapy. This case study suggests that
the field of protein structure prediction now offers signif-
icant modeling capability to approach complex prob-
lems. In addition, we closely combined docking with ex-
perimental mutagenesis information to solve the mAb
806-EGFR complex. Mutagenesis data for the interac-
tion of protein binding partners are quite frequently avail-
able or easily obtainable, but the complex structure is of-
ten unknown and less easily obtained. There is vigorous
interest in the development of therapeutic antibodies
against diverse indications such as cancer, inflamma-
tion, autoimmune disorders, and infectious diseases.
As both computational docking and mutagenesis be-
come more accurate with the inclusion of backbone flex-
ibility and sophisticated treatment of the electrostatic in-
teractions, our approach could be extremely useful for
integrating experimental data with docking studies for
this important class of protein-protein interactions.
Experimental Procedures
Starting Structures
mAb 806
The sequence (Old et al., 2002) of the mAb 806 Fv is as follows (the
CDR regions are in bold). Light chain: DILMTQSPSSMSVSLGDTV
SITCHSSQDINSNIGWLQQRPGKSFKGLIYHGTNLDDEVPSRFSG
SGSGADYSLTISSLESEDFADYYCVQYAQFPWTFGGGTKLEIKRA;
heavy chain: DVQLQESGPSLVKPSQSLSLTCTVTGYSITSDFAWN
WIRQFPGNKLEWMGYISYSGNTRYNPSLKSRISITRDTSKNQFFL
QLNSVTIEDTATYYCVTAGRGFPYWGQGTLVTVS. A single-chain
variable fragment homology model for antibody 806 was built by
using the Web Antibody Modeling (Whitelegg and Rees, 2000)
(WAM) server. This method finds the closest antibody homolog
for the light and heavy Fv region and then creates the conforma-
tions of the CDR loops from canonical classes by using a se-
quence-based algorithm with empirical rules. The rules typically
fail for the CDR H3 loop, and, in this case, its configuration is
determined with a combined database/conformational search.
Structure
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The five backbone conformations of the peptide epitope (EGFR res-
idues 287–302) are taken from the tethered monomer (1NQL, resolu-
tion 2.8 A˚) and the untethered homodimer crystal structures (1IVO,
resolution 3.3 A˚; 1MOX, resolution 2.5 A˚). Side chain coordinates
are missing for several peptide residues in crystal structures of the
dimer 1MOX (290, 295, and 299–301 in chain A; 290, 296, 300, and
301 in chain B) and the tethered monomer 1NQL (290, 293–297).
These are reconstructed during docking by using a backbone-de-
pendent rotamer library (Dunbrack and Cohen, 1997).
Docking
We use the RosettaDock algorithm for the mAb 806-peptide docking
simulations. We developed RosettaDock to predict a protein com-
plex structure from its unbound monomer components (Gray
et al., 2003b). Independent simulations are carried out in parallel,
and the resulting ‘‘decoys’’ are ranked by using a scoring function
dominated by van der Waals interactions, an implicit solvation
model (Lazaridis and Karplus, 1999), and an orientation-dependent
hydrogen bonding potential (Kortemme et al., 2003). We generate
105 docking decoys in a global docking search by sampling all orien-
tations of the peptide in the vicinity of the antibody CDRs, and we
use an alignment score to favor peptide contacts with the CDRs
(Gray et al., 2003a). The RosettaDock protocol is available free for
academic use at http://graylab.jhu.edu.
Computational Mutagenesis
The RosettaInterface computational mutagenesis approach (Kor-
temme and Baker, 2002) was used to estimate the change in the
binding free energy (DDG) for individual residue mutations. This al-
gorithm estimates DDG by modeling the residue mutation in both
the protein complex and the uncomplexed monomers using a back-
bone-dependent rotamer library. The energy function is similar to
the RosettaDock energy function and incorporates the solute-
solvent entropy and the solvent reorganization entropy via the
Lazaridis-Karplus implicit solvation model, but neglects the protein
configurational entropy. The RosettaInterface computational muta-
genesis server can be accessed at http://robetta.bakerlab.org.
Structural Superposition to Eliminate Unphysical mAb
806-Peptide Orientations
A comparative analysis of the tethered (1NQL) and untethered
(1MOX, 1IVO) EGFR crystal structures suggests that five residue
segments stay rigid, with relative motion amongst these segments
during the conformational change. The fragments, numbered 1–5,
are as follows: residues 3–240, containing all of domain I and parts
of domain II; residues 241–260, containing the dimerization arm; res-
idues 261–286 that occur prior to the mAb 806 epitope; residues
287–302, containing the epitope; and residues 310–512, containing
domain III. We calculated the separation between the centroids of
the peptide epitope and each of the other segments as defined
above individually for the tethered and the untethered states.
Then, we calculated the change in this centroid-centroid separation
between the tethered and the untethered states. This change in the
centroid-centroid separation between the peptide epitope and frag-
ments 1, 2, 3, and 5 are 7.1 A˚, 1.5 A˚, 0.4 A˚, and 29.4 A˚, respectively.
The magnitude of this change indicates the extent to which the seg-
ments move relative to the peptide epitope 287–302 due to the con-
formational transition. Since the change in the centroid-centroid
separation between fragment 3 (residues 261–286) and the epitope
due to the conformational change is negligible (<0.5 A˚), this implies
that fragment 261–302 moves as a rigid body.
The design of the structural superposition filter to eliminate phys-
ically unrealistic mAb 806-peptide orientations is as follows. For
a given docking decoy, we perform a least-squares structural super-
position of the Ca atoms of the peptide residues in the decoy and the
arbitrary tethered EGFR crystal structure (1NQL) by using PyMol
(DeLano, 2002). Since mAb 806 does not bind the tethered EGFR
in experiments, the superposition could legitimately result in clashes
of mAb 806 residues with the nonpeptide EGFR residues. These
clashes may be ‘‘minor’’ van der Waals bumps involving less than
5 residues from each protein, or they may result in segment-seg-
ment interpenetration involving more than 25 residues from each
protein. If the clashes are between mAb 806 and EGFR residue frag-ments that move relative to the peptide and away from it, it is theo-
retically possible for the EGFR residue fragments to rearrange them-
selves into an intermediate state to permit the mAb 806-peptide
orientation without any clashes. On the other hand, the clashes
might involve residue fragments that do not appear to move relative
to the peptide or move toward it. In this case, the clashes are likely to
persist during the conformational change, and such mAb 806-pep-
tide orientations are physically unrealistic. Therefore, we eliminated
from any further consideration all decoys that resulted in complete
interpenetration of mAb 806 and residue segment 261–286, since
this segment does not appear to move relative to the peptide epi-
tope between the tethered and untethered EGFR. We also elimi-
nated those decoys that displayed large interpenetration of more
than 25 residues with either segment 3–240 or segment 310–512.
By the same token, we retained decoys that had minor clashes of
less than 5 residues with any of the five residue segments. We
also produced animations of the EGFR conformational change by
using the Morph Server (Echols et al., 2003) and the Elastic Network
Interpolation method (Kim et al., 2003) to confirm our above-de-
scribed elimination strategy. While these interpolations do not nec-
essarily capture the biophysical pathway of the EGFR conforma-
tional change, they offer useful guidelines for interpreting the
results of the structural superposition.
Site-Directed Mutagenesis Experiments
Site-directed mutagenesis of EGFR and testing were performed as
described previously (Chao et al., 2004). Briefly, amino acid muta-
tions of EGFR fragment 273–621 in the yeast surface display plasmid
pCT302 were introduced by using mutagenic PCR primers. The mu-
tant plasmids were transformed into yeast strain EBY100 and were
galactose induced. Mutants on the surface of yeast were tested
for binding at 75 nM mAb 806 by using flow cytometry. mAb 806
was generously provided by the Ludwig Institute for Cancer Re-
search.
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